

The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies [Corrigendum]

Donohue JF, Ozol-Godfrey A, Goodin T, Sanjar S. *Int J Chron Obstruct Pulmon Dis*. 2020;15:745–754.

The correct **Figure 4** is shown below. The authors apologize for this error.

The authors have advised there is an error in **Figure 4** on page 751. The Q2 subgroup of the placebo arm has the label of “-0.012” which should read “0.012”.




Figure 4 Pooled analysis of change from baseline in trough FEV₁ at 12 weeks by baseline rescue medication use subgroup (ITT population).

Notes: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ versus placebo; n-values represent the number of patients with on-treatment data at week 12.

Abbreviations: BID, twice daily; FEV₁, forced expiratory volume in 1 second; GLY, nebulized glycopyrrolate; ITT, intent-to-treat; LS, least squares; Q, quarter; SE, standard error.

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management

protocols. This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal>